BAG6 specific chimeric antigen receptor as well as nucleic acid, expression plasmid, cell, application and pharmaceutical composition thereof

By expressing BAG6-specific chimeric antigen receptors in immune cells and using them to bind to BAG6, HLA-G and B7-H6 on the tumor cell membrane, the inefficient treatment of chimeric antigen receptors in the prior art is solved. The problem has achieved efficient targeted killing of tumor cells and significantly improved the cancer treatment effect.

CN118930656APending Publication Date: 2024-11-12National Taiwan Medical University Hospital
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410571152.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-08
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing chimeric antigen receptor immune cell therapy has low efficacy in solid tumors due to the lack of unique tumor-associated antigens and immunosuppressive microenvironment limitations.

Method used

Develop BAG6-specific chimeric antigen receptors, which can express BAG6-specific chimeric antigen receptors through gene transduction, and use them to specifically bind to BAG6, HLA-G and B7-H6 on the tumor cell membrane to activate immunity Targeted killing of tumor cells by cells.

Benefits of technology

It realizes the specific targeting and effective toxicity of immune cells on tumor cells, avoids off-target effects, significantly improves the mortality rate of tumor cells, and provides an efficient cancer treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930656A_ABST
    Figure CN118930656A_ABST
Patent Text Reader

Abstract

The invention provides a BAG6 specific chimeric antigen receptor, an isolated nucleic acid, a BAG6 specific chimeric antigen receptor expression plasmid, a receptor cell for expressing a BAG6 specific chimeric antigen, a pharmaceutical composition for treating cancers and application of the receptor cell for expressing the BAG6 specific chimeric antigen. The BAG6 specific chimeric antigen receptor is specifically combined with a BCL2 associated apoptosis gene 6. The receptor cell line for expressing the BAG6 specific chimeric antigen is obtained by transduction of the BAG6 specific chimeric antigen receptor into immune cells. A pharmaceutical composition for treating cancer comprises recipient cells expressing BAG6 specific chimeric antigen and a pharmaceutically acceptable carrier. Therefore, expression BAG6 specific chimeric antigen recipient cells can be used for inducing tumor cell death of mammals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical product containing an antigen or an antibody, in particular to a chimeric antigen receptor, a nucleic acid encoding a chimeric antigen receptor, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and a use of a chimeric antigen receptor expressing cell. Background Art

[0002] Cancer, also known as malignant tumor, is the abnormal proliferation of cells. These proliferating cells may invade other parts of the body. It is a disease caused by abnormal control of cell division and proliferation mechanism.

[0003] Conventional tumor treatment methods include surgery, radiotherapy, chemotherapy and targeted therapy, etc. Tumor immunotherapy is another method of treating tumors besides the above treatment methods. It activates the patient's own immune system, uses tumor cells or tumor antigens to induce the body's specific cellular immunity and humoral immune response, enhances the body's anti-cancer ability, prevents tumor growth, spread and recurrence, and achieves the purpose of eliminating or controlling tumors.

[0004] There are three main directions in tumor immunotherapy - tumor vaccines, cell therapy and immune checkpoint inhibitors, among which chimeric antigen receptor immune cell technology is a cell therapy that has developed very rapidly in recent years. In the known technology, chimeric antigen receptor immune cells are a chimeric protein that couples the antigen binding part of an antibody that can recognize a certain tumor antigen with the intracellular part of the CD3-δ chain or FcεRIγ in vitro, and transfects the patient's immune cells through gene transduction to express chimeric antigen receptors. It has a significant therapeutic effect in the treatment of acute leukemia and non-Hodgkin's lymphoma and is considered to be one of the most promising tumor treatment methods. However, the current cell therapy of chimeric antigen receptor immune cells is greatly limited in its efficacy in solid tumors due to the lack of unique tumor-associated antigens, the low efficiency of immune cells homing to the tumor location, and the inability to overcome the immunosuppressive microenvironment of solid tumors. Summary of the invention

[0005] The purpose of the present invention is to provide a BAG6-specific chimeric antigen receptor, an isolated nucleic acid, a BAG6-specific chimeric antigen receptor expression plasmid, a BAG6-specific chimeric antigen receptor expression cell, a pharmaceutical composition for treating cancer, and a use of a BAG6-specific chimeric antigen receptor expression cell. The BAG6-specific chimeric antigen receptor has excellent specific binding ability to tumor cells. The nucleic acid encodes the BAG6-specific chimeric antigen receptor. The BAG6-specific chimeric antigen receptor expression plasmid comprises the nucleic acid. The BAG6-specific chimeric antigen receptor expression cell comprises the BAG6-specific chimeric antigen receptor expression plasmid, which expresses the BAG6-specific chimeric antigen receptor, can specifically target tumor cells, avoid off-target effects, and effectively kill tumor cells, so that it can be used to prepare a drug that induces tumor cell death in mammals. The pharmaceutical composition for treating cancer comprises the BAG6-specific chimeric antigen receptor expression cell, which can effectively kill tumor cells and treat cancer.

[0006] One aspect of the present invention is to provide a BAG6-specific chimeric antigen receptor that specifically binds to BCL2 associated athanogene 6 (BAG6). The BAG6-specific chimeric antigen receptor comprises a BAG6 antigen recognition domain, a transmembrane domain, and a cytoplasmic domain arranged in sequence from the N-terminus to the C-terminus. The BAG6 antigen recognition domain comprises a monoclonal antibody fragment specific to BAG6, and the amino acid sequence of the BAG6 antigen recognition domain is shown in SEQ ID NO: 1.

[0007] According to the aforementioned BAG6-specific chimeric antigen receptor, it may further comprise an HLA-G antigen recognition domain as shown in SEQ ID NO:2, which is connected to the C-terminus of the BAG6 antigen recognition domain, and the HLA-G antigen recognition domain comprises a monoclonal antibody fragment specific to human leukocyte antigen G (HLA-G).

[0008] According to the aforementioned BAG6-specific chimeric antigen receptor, it may further comprise a B7-H6 antigen recognition domain as shown in SEQ ID NO:3, which is connected to the C-terminus of the BAG6 antigen recognition domain, and the B7-H6 antigen recognition domain comprises a monoclonal antibody fragment specific to B7-H6 (B7 homolog 6).

[0009] According to the aforementioned BAG6-specific chimeric antigen receptor, the transmembrane domain may be the CD28 transmembrane domain shown in SEQ ID NO:4, the CD8 transmembrane domain shown in SEQ ID NO:5, or the KIR transmembrane domain shown in SEQ ID NO:6.

[0010] According to the aforementioned BAG6-specific chimeric antigen receptor, the cytoplasmic domain may be the IL2 receptor β chain signaling domain shown in SEQ ID NO:7, the modified CD3ζ signaling domain shown in SEQ ID NO:8, a DAP12 signaling domain shown in SEQ ID NO:9, a CD3ζ signaling domain shown in SEQ ID NO:10, a 4-1BB signaling domain shown in SEQ ID NO:11, or a combination thereof.

[0011] According to the aforementioned BAG6-specific chimeric antigen receptor, it may further comprise a suicide protein as shown in SEQ ID NO: 12, which is connected to the C-terminus of the cytoplasmic domain.

[0012] Another aspect of the present invention is to provide an isolated nucleic acid encoding the BAG6-specific chimeric antigen receptor as described in the preceding paragraph, wherein the nucleic acid comprises a fragment encoding a BAG6 antigen recognition domain, a fragment encoding a transmembrane domain, and a fragment encoding a cytoplasmic domain as shown in SEQ ID NO: 13 arranged in sequence.

[0013] The isolated nucleic acid described above may further comprise a fragment encoding an HLA-G antigen recognition domain as shown in SEQ ID NO: 14, which is connected to the 3' end of the fragment encoding the BAG6 antigen recognition domain.

[0014] The isolated nucleic acid described above may further comprise a fragment encoding the B7-H6 antigen recognition domain as shown in SEQ ID NO: 15, which is connected to the 3' end of the fragment encoding the BAG6 antigen recognition domain.

[0015] According to the aforementioned isolated nucleic acid, the transmembrane domain encoding fragment may be the CD28 transmembrane domain encoding fragment shown in SEQ ID NO:16, the CD8 transmembrane domain encoding fragment shown in SEQ ID NO:17, or the KIR transmembrane domain encoding fragment shown in SEQ ID NO:18.

[0016] According to the aforementioned isolated nucleic acid, the cytoplasmic domain encoding fragment may be the IL2 receptor β chain signaling domain encoding fragment shown in SEQ ID NO:19, the modified CD3ζ signaling domain encoding fragment shown in SEQ ID NO:20, the DAP12 signaling domain encoding fragment shown in SEQ ID NO:21, the CD3ζ signaling domain encoding fragment shown in SEQ ID NO:22, the 4-1BB signaling domain encoding fragment shown in SEQ ID NO:23, or a combination thereof.

[0017] The isolated nucleic acid described above may further comprise a suicide gene as shown in SEQ ID NO: 24, which is connected to the 3' end of the fragment encoding the cytoplasmic domain.

[0018] Another aspect of the present invention is to provide a BAG6-specific chimeric antigen receptor expression plasmid, comprising the promoter shown in SEQ ID NO: 25 and the isolated nucleic acid as described in the previous paragraph arranged in sequence.

[0019] The aforementioned BAG6-specific chimeric antigen receptor expression plasmid may further comprise a suicide gene as shown in SEQ ID NO: 24, which is connected to the 3' end of the nucleic acid.

[0020] Another aspect of the present invention is to provide a cell expressing a BAG6-specific chimeric antigen receptor, comprising an immune cell and the BAG6-specific chimeric antigen receptor expression plasmid as described in the preceding paragraph.

[0021] According to the aforementioned BAG6-specific chimeric antigen receptor cells, the immune cells may be T cells or natural killer cells.

[0022] Another aspect of the present invention is to provide a pharmaceutical composition for treating cancer, comprising the BAG6-specific chimeric antigen receptor cell expressed as described in the preceding paragraph and a pharmaceutically acceptable carrier.

[0023] The aforementioned pharmaceutical composition for treating cancer may further comprise a chemotherapeutic drug.

[0024] According to the aforementioned pharmaceutical composition for treating cancer, the chemotherapy drug may be doxorubicin, temozolomide, gemcitabine or carboplatin.

[0025] Another aspect of the present invention is to provide a use of a cell expressing a BAG6-specific chimeric antigen receptor for preparing a drug for inducing death of a tumor cell in a mammal, wherein the tumor cell is a breast cancer cell, a glioblastoma multiforme cell, a pancreatic cancer cell or an ovarian cancer cell.

[0026] The above invention summary is intended to provide a simplified summary of the present disclosure so that readers can have a basic understanding of the present disclosure. This invention summary is not a complete overview of the present disclosure, and its intention is not to point out the important / critical components of the embodiments of the present invention or to define the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to make the above and other objects, features, advantages and embodiments of the present invention more clearly understood, the following are the descriptions of the accompanying drawings:

[0028] Figure 1 A schematic diagram showing the construction of a BAG6-specific chimeric antigen receptor according to one aspect of the present invention is shown;

[0029] Figure 2AThis is the result of immunofluorescence staining of BAG6 expression in tumor cells after chemotherapy;

[0030] Figure 2B This is the result of flow cytometry analysis of BAG6 expression in tumor cells after chemotherapy;

[0031] Figure 3 This is the result of flow cytometry analysis of HLA-G expression in tumor cells after chemotherapy;

[0032] Figure 4 This is a flow cytometric analysis result of B7-H6 expression in tumor cells after chemotherapy;

[0033] Figure 5 A schematic diagram showing the construction of a BAG6-specific chimeric antigen receptor expression plasmid according to another embodiment of the present invention is shown;

[0034] Figure 6 A schematic diagram showing the theoretical structure and mechanism of action of a BAG6-specific chimeric antigen receptor according to one embodiment of one aspect of the present invention is shown;

[0035] Fig. 7A , Figure 7B , Figure 7C , Fig.7D , Fig. 7E , Figure 7F , Figure 7G and Figure 7H This is a diagram showing the analysis results of tumor cell death induced by cells expressing BAG6-specific chimeric antigen receptor according to Example 1 of the present invention;

[0036] Fig. 8A , Figure 8B , Figure 8C , Fig.8D , Fig. 8E , Figure 8F , Figure 8G and Figure 8H This is a diagram showing the analysis results of tumor cell death induced by cells expressing BAG6-specific chimeric antigen receptor according to Example 2 of the present invention;

[0037] Fig. 9 A schematic diagram showing the construction of a BAG6-specific chimeric antigen receptor expression plasmid according to another embodiment of another aspect of the present invention is shown;

[0038] Fig.10 A schematic diagram showing the theoretical structure and mechanism of action of a BAG6-specific chimeric antigen receptor according to another embodiment of one aspect of the present invention is shown;

[0039] Fig.11A , Fig. 11B , Fig. 11C , Fig.11D , Fig.11E , Fig.11F , Fig.11G and Fig.11H This is a diagram showing the analysis results of tumor cell death induced by cells expressing BAG6-specific chimeric antigen receptor according to Example 3 of the present invention;

[0040] Fig. 12A , Fig. 12B , Fig. 12C , Fig.12D , Fig.12E , Fig.12F , Figure 12G and Fig.12H This is a diagram showing the analysis results of tumor cell death induced by cells expressing BAG6-specific chimeric antigen receptor according to Example 4 of the present invention;

[0041] Fig.13 A schematic diagram showing the construction of a BAG6-specific chimeric antigen receptor expression plasmid according to yet another embodiment of another aspect of the present invention is shown;

[0042] Fig.14 A schematic diagram showing the theoretical structure and action mechanism of a BAG6-specific chimeric antigen receptor according to yet another embodiment of one aspect of the present invention is shown;

[0043] Fig.15A , Fig. 15B , Fig. 15C , Fig.15D , Fig.15E , Fig.15F , Figure 15G and Fig.15H This is a diagram showing the analysis results of inducing tumor cell death by cells expressing BAG6-specific chimeric antigen receptor according to Example 5 of the present invention; and

[0044] Fig.16A , Fig. 16B , Fig. 16C , Fig.16D , Fig.16E , Fig.16F , Figure 16G and Fig.16H This is a diagram showing the analysis results of Example 6 of the present invention showing that cells expressing BAG6-specific chimeric antigen receptor induce tumor cell death.

[0045]

Explanation of symbols

[0046] 100:BAG6-specific chimeric antigen receptor

[0047] 110:BAG6 antigen recognition domain

[0048] 130: transmembrane domain

[0049] 140: Cytoplasmic domain DETAILED DESCRIPTION

[0050] The present specification discloses a BAG6-specific chimeric antigen receptor, a nucleic acid encoding the BAG6-specific chimeric antigen receptor, a BAG6-specific chimeric antigen receptor expression plasmid comprising the nucleic acid, a BAG6-specific chimeric antigen receptor-expressing cell comprising the BAG6-specific chimeric antigen receptor expression plasmid, uses thereof, and a pharmaceutical composition for treating cancer comprising a BAG6-specific chimeric antigen receptor-expressing cell.

[0051] Please refer to Figure 1 , depicts a schematic diagram of the construction of a BAG6-specific chimeric antigen receptor 100 of one aspect of the present invention. The BAG6-specific chimeric antigen receptor 100 specifically binds to BCL2associated athanogene 6 (BAG6). The BAG6-specific chimeric antigen receptor 100 comprises a BAG6 antigen recognition domain 110, a transmembrane domain 130, and a cytoplasmic domain 140 arranged in sequence from the N-terminus to the C-terminus. The BAG6 antigen recognition domain 110 comprises a monoclonal antibody fragment specific to BAG6, and the amino acid sequence of the BAG6 antigen recognition domain 110 is shown in SEQ ID NO: 1. The BAG6-specific chimeric antigen receptor 100 may further include an HLA-G antigen recognition domain as shown in SEQ ID NO: 2, which is connected to the C-terminus of the BAG6 antigen recognition domain 110, and the HLA-G antigen recognition domain includes a monoclonal antibody fragment specific to human leukocyte antigen G (HLA-G). In addition, the BAG6-specific chimeric antigen receptor 100 may further include a B7-H6 antigen recognition domain as shown in SEQ ID NO: 3, which is connected to the C-terminus of the BAG6 antigen recognition domain 110. The B7-H6 antigen recognition domain includes a monoclonal antibody fragment specific to B7-H6 (B7 homolog 6).

[0052] The transmembrane domain 130 of the BAG6-specific chimeric antigen receptor 100 may be a CD28 transmembrane domain as shown in SEQ ID NO: 4, a CD8 transmembrane domain as shown in SEQ ID NO: 5, or a KIR transmembrane domain as shown in SEQ ID NO: 6. The cytoplasmic domain 140 may be an IL2 receptor β chain signaling domain as shown in SEQ ID NO: 7, a modified CD3 ζ signaling domain as shown in SEQ ID NO: 8, a DAP12 signaling domain as shown in SEQ ID NO: 9, a CD3 ζ signaling domain as shown in SEQ ID NO: 10, a 4-1BB signaling domain as shown in SEQ ID NO: 11, or a combination thereof. The BAG6-specific chimeric antigen receptor 100 may further include a suicide protein as shown in SEQ ID NO: 12, which is connected to the C-terminus of the cytoplasmic domain 140.

[0053] Another aspect of the present invention is an isolated nucleic acid, which encodes the BAG6-specific chimeric antigen receptor 100 as described in the preceding paragraph. The nucleic acid comprises a BAG6 antigen recognition domain fragment, a transmembrane domain fragment, and a cytoplasmic domain fragment, which are arranged in sequence as shown in SEQ ID NO: 13. The nucleic acid may further comprise an HLA-G antigen recognition domain fragment as shown in SEQ ID NO: 14, which is connected to the 3' end of the BAG6 antigen recognition domain fragment. In addition, the nucleic acid may further comprise a B7-H6 antigen recognition domain fragment as shown in SEQ ID NO: 15, which is connected to the 3' end of the BAG6 antigen recognition domain fragment.

[0054] The transmembrane domain fragment encoded by the nucleic acid may be a CD28 transmembrane domain fragment encoded by SEQ ID NO: 16, a CD8 transmembrane domain fragment encoded by SEQ ID NO: 17, or a KIR transmembrane domain fragment encoded by SEQ ID NO: 18. The cytoplasmic domain fragment encoded by the nucleic acid may be a fragment encoding the IL2 receptor β chain signaling domain as shown in SEQ ID NO: 19, a fragment encoding the modified CD3 ζ signaling domain as shown in SEQ ID NO: 20, a fragment encoding the DAP12 signaling domain as shown in SEQ ID NO: 21, a fragment encoding the CD3 ζ signaling domain as shown in SEQ ID NO: 22, a fragment encoding the 4-1BB signaling domain as shown in SEQ ID NO: 23, or a combination thereof. In addition, the nucleic acid may further comprise a suicide gene as shown in SEQ ID NO: 24, which is connected to the 3' end of the cytoplasmic domain fragment encoded.

[0055] Another aspect of the present invention is a BAG6-specific chimeric antigen receptor expression plasmid, which comprises the promoter shown in SEQ ID NO: 25 and the nucleic acid described in the previous paragraph. In addition, the BAG6-specific chimeric antigen receptor expression plasmid may further comprise a suicide gene shown in SEQ ID NO: 24, which is connected to the 3' end of the nucleic acid.

[0056] Another aspect of the present invention is a cell expressing a BAG6-specific chimeric antigen receptor, comprising an immune cell and a BAG6-specific chimeric antigen receptor expression plasmid as described in the previous paragraph, wherein the immune cell may be a T cell or a natural killer cell.

[0057] Another aspect of the present invention is to provide a pharmaceutical composition for treating cancer, comprising a cell expressing a BAG6-specific chimeric antigen receptor as described in the preceding paragraph and a pharmaceutically acceptable carrier. The pharmaceutical composition for treating cancer may further comprise a chemotherapeutic drug. Preferably, the chemotherapeutic drug may be doxorubicin, temozolomide, gemcitabine or carboplatin.

[0058] Another aspect of the present invention is to provide a use of a cell expressing a BAG6-specific chimeric antigen receptor for preparing a drug for inducing tumor cell death in mammals. The tumor cell may be a breast cancer cell, a glioblastoma multiforme cell, a pancreatic cancer cell or an ovarian cancer cell.

[0059] The cell test of tumor cells in the specification proves that the BAG6-specific chimeric antigen receptor of the present invention has excellent specific binding ability to tumor cells, especially specific binding to BAG6 expressed on the cell membrane of tumor cells, so that the BAG6-specific chimeric antigen receptor expressing cells expressing the BAG6-specific chimeric antigen receptor of the present invention can specifically target tumor cells, avoid off-target effects, and effectively kill tumor cells, so that it can be used to prepare drugs that induce tumor cell death in mammals. The pharmaceutical composition for treating cancer of the present invention comprises the BAG6-specific chimeric antigen receptor expressing cells of the present invention and a pharmaceutically acceptable carrier, and may further comprise chemotherapeutic drugs, which can effectively kill tumor cells and treat cancer.

[0060] The present invention is further illustrated by the following specific test examples, which are used to facilitate those skilled in the art to which the present invention belongs, so that the present invention can be fully utilized and practiced without excessive interpretation. These test examples should not be regarded as limiting the scope of the present invention, but are used to illustrate how to implement the materials and methods of the present invention.

[0061] 1. Treatment with chemotherapy drugs increases the expression of BAG6, HLA-G and B7-H6 on the cell membrane of tumor cells

[0062] This experiment first explored whether the treatment of chemotherapy drugs would affect the expression of BAG6, HLA-G and B7-H6 on the cell membrane of tumor cells. The tumor cells used in the experiment were human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG-05MG (hereinafter referred to as DBTRG), human pancreatic cancer cell line AsPC-1 and human ovarian cancer cell line SKOV3. The tumor cell lines used were all purchased from the American Type Culture Collection (ATCC). The human breast cancer cell line MDA-MB-231 cell line is a triple-negative breast cancer cell line, that is, hormone receptors (ER, PR) and HER-2 receptors are negative, and it is cultured in RPMI culture medium containing 10% fetal bovine serum (FBS). The human malignant brain tumor cell line DBTRG was cultured in DMEM culture medium containing 10% fetal bovine serum. The human pancreatic cancer cell line AsPC-1 was cultured in RPMI culture medium containing 10% fetal bovine serum. Human ovarian cancer cell line SKOV3 was cultured in McCoy's 5A medium containing 10% fetal bovine serum.

[0063] Human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG, human pancreatic cancer cell line AsPC-1, and human ovarian cancer cell line SKOV3 were seeded in a 6-well plate at a density of 2×105 cells / well, and then cultured until the next day for cell attachment before the experiment. In the experiment, each tumor cell was divided into two groups, an untreated control group and a chemotherapy group treated with chemotherapy drugs for 48 hours. The chemotherapy drug used in the group of human breast cancer cell line MDA-MB-231 was doxorubicin (200nM); the chemotherapy drug used in the group of human malignant brain tumor cell line DBTRG was temozolomide (80μg / mL); the chemotherapy drug used in the group of human pancreatic cancer cell line AsPC-1 was gemcitabine (20μM); and the chemotherapy drug used in the group of human ovarian cancer cell line SKOV3 was carboplatin (20μM). The treated tumor cells in each group were then subjected to immunofluorescence staining to detect the expression of BAG6 on the cell surface of the tumor cells, and flow cytometry was used to detect the expression of BAG6, HLA-G and B7-H6 on the cell surface of the tumor cells.

[0064] Please refer to Figure 2A and Figure 2B , Figure 2A This is the immunofluorescence staining result of BAG6 expression in tumor cells after chemotherapy. Figure 2BThis is the result of flow cytometry analysis of BAG6 expression in tumor cells after chemotherapy.

[0065] Depend on Figure 2A and Figure 2B The results showed that treatment with doxorubicin increased the expression of BAG6 on the cell membrane of human breast cancer cell line MDA-MB-231, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with temozolomide increased the expression of BAG6 on the cell membrane of human malignant brain tumor cell line DBTRG, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.01). Treatment with gemcitabine increased the expression of BAG6 on the cell membrane of human pancreatic cancer cell line AsPC-1, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with carboplatin increased the expression of BAG6 on the cell membrane of human ovarian cancer cell line SKOV3, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001).

[0066] Please refer to Figure 3 , which is the result of flow cytometry analysis of HLA-G expression after tumor cells received chemotherapy. The results showed that treatment with doxorubicin increased the expression of HLA-G on the cell membrane of human breast cancer cell line MDA-MB-231, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with temozolomide increased the expression of HLA-G on the cell membrane of human malignant brain tumor cell line DBTRG, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with gemcitabine increased the expression of HLA-G on the cell membrane of human pancreatic cancer cell line AsPC-1, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with carboplatin increased the expression of HLA-G on the cell membrane of human ovarian cancer cell line SKOV3, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001).

[0067] Please refer to Figure 4, which is the result of flow cytometry analysis of B7-H6 expression in tumor cells after chemotherapy. The results showed that treatment with doxorubicin increased the expression of B7-H6 on the cell membrane of human breast cancer cell line MDA-MB-231, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with temozolomide increased the expression of B7-H6 on the cell membrane of human malignant brain tumor cell line DBTRG, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with gemcitabine increased the expression of B7-H6 on the cell membrane of human pancreatic cancer cell line AsPC-1, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001). Treatment with carboplatin increased the expression of B7-H6 on the cell membrane of human ovarian cancer cell line SKOV3, and there was a statistically significant difference between the control group and the chemotherapy group (p<0.001).

[0068] 2. Implementation Method 1

[0069] The BAG6-specific chimeric antigen receptor of the first embodiment comprises the BAG6 antigen recognition domain shown in SEQ ID NO: 1, the CD28 transmembrane domain shown in SEQ ID NO: 4, the IL2 receptor β chain signaling domain shown in SEQ ID NO: 7, and the modified CD3ζ signaling domain shown in SEQ ID NO: 8, which are arranged in sequence from the N-terminus to the C-terminus. The nucleic acid of the first embodiment comprises the fragment encoding the BAG6 antigen recognition domain shown in SEQ ID NO: 13, the fragment encoding the CD28 transmembrane domain shown in SEQ ID NO: 16, the fragment encoding the IL2 receptor β chain signaling domain shown in SEQ ID NO: 19, and the fragment encoding the modified CD3ζ signaling domain shown in SEQ ID NO: 20.

[0070] Please refer to Figure 5, depicting a schematic diagram of the construction of a BAG6-specific chimeric antigen receptor expression plasmid according to Embodiment 1 of the present invention. In detail, the BAG6-specific chimeric antigen receptor expression plasmid according to Embodiment 1, its insert fragment comprises a promoter shown in SEQ ID NO:25, a fragment encoding a BAG6 antigen recognition domain shown in SEQ ID NO:13, a fragment encoding a CD28 transmembrane domain shown in SEQ ID NO:16, and a fragment encoding a cytoplasmic domain, wherein the fragment encoding the cytoplasmic domain comprises a fragment encoding an IL2 receptor β chain signaling domain shown in SEQ ID NO:19 and a fragment encoding a modified CD3ζ signaling domain shown in SEQ ID NO:20. The insert fragment is then constructed on a Creative Biolabs vector (Creative Biolabs, NY, USA) to obtain the BAG6-specific chimeric antigen receptor expression plasmid according to Embodiment 1. The vector used is a lentivirus vector system, so the constructed BAG6-specific chimeric antigen receptor expression plasmid of Implementation Method 1 can be transfected into expression cells to produce lentivirus, and then the BAG6-specific chimeric antigen receptor expression plasmid of Implementation Method 1 can be transduced into immune cells using the lentivirus.

[0071] Please refer to Figure 6 , depicting a schematic diagram of the theoretical structure and mechanism of action of the BAG6-specific chimeric antigen receptor of the first embodiment. The cell expressing the BAG6-specific chimeric antigen receptor of the first embodiment is a genetically engineered natural killer cell or T cell, which expresses the BAG6-specific chimeric antigen receptor of the first embodiment, and the BAG6-specific chimeric antigen receptor system is a tumor-targeting receptor complex composed of a BAG6 antigen recognition domain, a CD28 transmembrane domain and a cytoplasmic domain, wherein the cytoplasmic domain contains an IL2 receptor β chain signaling domain and a modified CD3ζ signaling domain. The BAG6-specific chimeric antigen receptor can specifically recognize BAG6 on the tumor cell membrane, thereby toxicating the tumor cells. Preferably, when tumor cells are treated with chemotherapeutic drugs, the BAG6 in the cell nucleus can be translocated to the plasma membrane of the tumor cell, and the BAG6-specific chimeric antigen receptor binds to the BAG6 specifically recognized on the surface of the tumor cell, triggering signal transduction, generating a signal cascade leading to the activation and proliferation of the BAG6-specific chimeric antigen receptor expressing cell of the present invention, thereby triggering the exocytosis of lytic particles and killing the target tumor cells.

[0072] 2.1. Example 1

[0073] In this test example, the BAG6-specific chimeric antigen receptor of embodiment 1 of the present invention is transduced into primary T cells to obtain cells expressing the BAG6-specific chimeric antigen receptor of embodiment 1 of the present invention (hereinafter referred to as "Example 1"). The effect of Example 1 and a pharmaceutical composition for treating cancer comprising Example 1 on inducing death of breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells and ovarian cancer cells was further tested.

[0074] First, human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG, human pancreatic cancer cell line AsPC-1 and human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells / well, and then cultured for 48 hours before testing. In the test, each tumor cell was divided into 6 groups, namely, an untreated control group, a test group 1 treated with chemotherapeutic drugs, a test group 2 treated with parental primary T cells, a test group 3 treated with parental primary T cells and chemotherapeutic drugs, a test group 4 treated with Example 1, and a test group 5 treated with Example 1 and chemotherapeutic drugs. In the group of human breast cancer cell line MDA-MB-231, the chemotherapy drug used was doxorubicin (200nM); in the group of human malignant brain tumor cell line DBTRG, the chemotherapy drug used was temozolomide (80μg / mL); in the group of human pancreatic cancer cell line AsPC-1, the chemotherapy drug used was gemcitabine (20μM); in the group of human ovarian cancer cell line SKOV3, the chemotherapy drug used was carboplatin (20μM). In test group 4 and test group 5, the number of cells of Example 1 treated was 1×105, and the number of parental primary T cells treated in test group 2 and test group 3 was also 1×105. The treated cells in each group were then stained with Annexin V-FITC and PI, and the apoptosis and death of cells were detected by flow cytometry, and the total percentage of cells stained with Annexin V-FITC and / or PI was calculated to obtain the cytotoxic effect. Each group was tested independently in triplicate, and the cytotoxicity results were statistically analyzed.

[0075] Please refer to Fig. 7A , Figure 7B , Figure 7C , Fig.7D , Fig. 7E , Figure 7F , Figure 7G , Figure 7H Table 1 is a graph showing the analysis results of inducing tumor cell death in Example 1, wherein Figure 7B , Fig.7D , Figure 7F and Figure 7HThe "P" in the figure represents the parental primary T cells. Figure 7A shows the analysis results of the human breast cancer cell line MDA-MB-231, and Figure 7B shows the analysis results of Figure 7A. Figure 3 Statistical graph after repeated experiments. Figure 7C This is the analysis result of human malignant brain tumor cell line DBTRG. Fig.7D for Figure 7C Statistical graph after three repeated experiments. Fig. 7E This is the analysis result of human pancreatic cancer cell line AsPC-1. Figure 7F for Fig. 7E Statistical graph after three repeated experiments. Figure 7G Figure 7H shows the analysis results of human ovarian cancer cell line SKOV3. Figure 7G Statistical graphs after three repeated experiments. Table 1 shows the mortality rate of each experimental group.

[0076] Table 1. Test results of Example 1

[0077]

[0078] From Table 1, Fig. 7A and Figure 7B The results showed that in the test groups of human breast cancer cell line MDA-MB-231, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 4 of treatment example 1 was about 47%, which was statistically significant compared with test group 2 (p<0.001). In addition, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 5 of treatment example 1 and doxorubicin was as high as 67.7%, which was statistically significant compared with test group 4 (p<0.05), and also statistically significant compared with test group 3 (p<0.001).

[0079] From Table 1, Figure 7C and Fig.7D The results showed that among the test groups of human malignant brain tumor cell line DBTRG, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 4 of Treatment Example 1 was 18.4%, which was statistically significant compared with Test Group 2 (p<0.05). In addition, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 5 of Treatment Example 1 and temozolomide was close to 67.2%, which was statistically significant compared with Test Group 4 (p<0.001), and also statistically significant compared with Test Group 3 (p<0.001).

[0080] From Table 1, Fig. 7E and Figure 7FThe results showed that in the test groups of human pancreatic cancer cell line AsPC-1, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 4 of treatment example 1 was about 22.9%, which was statistically significant compared with test group 2 (p<0.001). In addition, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 5 of treatment example 1 and gemcitabine was about 35.4%, which was statistically significant compared with test group 4 (p<0.05), and also statistically significant compared with test group 3 (p<0.05).

[0081] From Table 1, Figure 7G and Figure 7H The results showed that among the test groups of human ovarian cancer cell line SKOV3, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 4 of treatment example 1 was about 5.5%, and the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 5 of treatment example 1 and carboplatin was close to 59.8%, which was statistically significant compared with test group 4 (p<0.001) and also statistically significant compared with test group 3 (p<0.001).

[0082] 2.2. Example 2

[0083] In this test example, the BAG6-specific chimeric antigen receptor of embodiment 1 of the present invention is transduced into primary natural killer cells to obtain cells expressing the BAG6-specific chimeric antigen receptor of embodiment 2 of the present invention (hereinafter referred to as "Example 2"). The effect of Example 2 and a pharmaceutical composition for treating cancer comprising Example 2 on inducing death of breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells and ovarian cancer cells was further tested.

[0084] First, human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG, human pancreatic cancer cell line AsPC-1 and human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells / well, and then cultured for 48 hours before testing. In the test, each tumor cell was divided into 6 groups, namely, an untreated control group, a test group 1 treated with chemotherapeutic drugs, a test group 2 treated with parental primary natural killer cells, a test group 3 treated with parental primary natural killer cells and chemotherapeutic drugs, a test group 4 treated with Example 2, and a test group 5 treated with Example 2 and chemotherapeutic drugs. In the group of human breast cancer cell line MDA-MB-231, the chemotherapy drug used was doxorubicin (200nM); in the group of human malignant brain tumor cell line DBTRG, the chemotherapy drug used was temozolomide (80μg / mL); in the group of human pancreatic cancer cell line AsPC-1, the chemotherapy drug used was gemcitabine (20μM); in the group of human ovarian cancer cell line SKOV3, the chemotherapy drug used was carboplatin (20μM). In test groups 4 and 5, the number of cells of Example 2 treated was 1×105, and the number of cells of parental primary natural killer cells treated in test groups 2 and 3 was also 1×105. The treated cells in each group were then stained with Annexin V-FITC and PI, and the total percentage of cells stained with Annexin V-FITC and / or PI was calculated to obtain the cytotoxic effect. After three independent replicates were performed for each group, the cytotoxic effect results were statistically analyzed.

[0085] Please refer to Fig. 8A , Figure 8B , Figure 8C , Fig.8D , Fig. 8E , Figure 8F , Figure 8G , Figure 8H Table 2 is a graph showing the analysis results of inducing tumor cell death in Example 2, wherein Figure 8B , Fig.8D , Figure 8F and Figure 8H The "P" in the expression represents parental primary natural killer cells. Fig. 8A This is the analysis result of human breast cancer cell line MDA-MB-231. Figure 8B for Fig. 8A Statistical graph after three repeated experiments. Figure 8C This is the analysis result of human malignant brain tumor cell line DBTRG. Fig.8D for Figure 8C Statistical graph after three repeated experiments. Fig. 8E This is the analysis result of human pancreatic cancer cell line AsPC-1. Figure 8F for Fig. 8EStatistical graph after three repeated experiments. Figure 8G This is the analysis result of human ovarian cancer cell line SKOV3. Figure 8H for Figure 8G The statistical graph after three repeated experiments. Table 2 shows the mortality rate of each experimental group.

[0086] Table 2. Test results of Example 2

[0087]

[0088] From Table 2, Fig. 8A and Figure 8B The results showed that in the test groups of human breast cancer cell line MDA-MB-231, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 4 of treatment example 2 was about 12.3%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 5 of treatment example 2 and doxorubicin was as high as more than 80%, which was statistically significant compared with test group 4 (p<0.001), and also statistically significant compared with test group 3 (p<0.001).

[0089] From Table 2, Figure 8C and Fig.8D The results showed that among the test groups of human malignant brain tumor cell line DBTRG, the mortality rate of human malignant brain tumor cell line DBTRG induced by test group 4 of treatment example 2 was about 21.7%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human malignant brain tumor cell line DBTRG induced by test group 5 of treatment example 2 and temozolomide was close to 66.2%, which was statistically significant compared with test group 4 (p<0.001), and also statistically significant compared with test group 3 (p<0.001).

[0090] From Table 2, Fig. 8E and Figure 8F The results showed that, among the test groups of human pancreatic cancer cell line AsPC-1, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by Test Group 4 of Treatment Example 2 was about 17.2%, and the mortality rate of human pancreatic cancer cell line AsPC-1 induced by Test Group 5 of Treatment Example 2 and gemcitabine was about 52.9%, which was statistically significant compared with Test Group 4 (p<0.001) and also statistically significant compared with Test Group 3 (p<0.05).

[0091] From Table 2, Figure 8G and Figure 8HThe results showed that in the test groups of human ovarian cancer cell line SKOV3, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 4 of treatment example 2 was about 14.9%, which was statistically significant compared with test group 2 (p<0.05). In addition, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 5 of treatment example 2 and carboplatin was more than 80%, which was statistically significant compared with test group 4 (p<0.001) and also statistically significant compared with test group 3 (p<0.001).

[0092] From Table 1, Table 2 and 7A to 8H The results show that the BAG6-specific chimeric antigen receptor cells of the first embodiment have excellent cytotoxic effects on breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells or ovarian cancer cells. Therefore, the BAG6-specific chimeric antigen receptor cells of the present invention can be used to prepare drugs for inducing tumor cell death in mammals. Figure 2A and Figure 2B The results show that treatment with chemotherapy drugs can increase the expression of BAG6 on the cell membrane of tumor cells, and the BAG6-specific chimeric antigen receptor expressed by the BAG6-specific chimeric antigen receptor expressing cells of embodiment 1 can specifically bind to BAG6, so that treating the BAG6-specific chimeric antigen receptor expressing cells of embodiment 1 after treating chemotherapy drugs, or treating the BAG6-specific chimeric antigen receptor expressing cells of embodiment 1 and chemotherapy drugs at the same time can have a better effect of killing tumor cells. It shows that the pharmaceutical composition for treating cancer of the present invention can preferably contain chemotherapy drugs, which can effectively kill tumor cells and thus treat cancer.

[0093] 3. Implementation Method 2

[0094] The BAG6-specific chimeric antigen receptor of the second embodiment comprises the BAG6 antigen recognition domain shown in SEQ ID NO:1, the HLA-G antigen recognition domain shown in SEQ ID NO:2, the KIR transmembrane domain shown in SEQ ID NO:6, and the DAP12 signaling domain shown in SEQ ID NO:9, which are arranged in sequence from the N-terminus to the C-terminus. In addition, the BAG6-specific chimeric antigen receptor of the second embodiment may further comprise the suicide protein shown in SEQ ID NO:12, which is connected to the C-terminus of the DAP12 signaling domain. The nucleic acid of the second embodiment comprises the fragment encoding the BAG6 antigen recognition domain shown in SEQ ID NO:13, the fragment encoding the HLA-G antigen recognition domain shown in SEQ ID NO:14, the fragment encoding the KIR transmembrane domain shown in SEQ ID NO:18, and the fragment encoding the DAP12 signaling domain shown in SEQ ID NO:21. In addition, the nucleic acid of the second embodiment may further comprise the suicide gene shown in SEQ ID NO:24, which is connected to the 3' end of the fragment encoding the DAP12 signaling domain.

[0095] Please refer to Fig. 9 , depicting a schematic diagram of the construction of a BAG6-specific chimeric antigen receptor expression plasmid according to the second embodiment of the present invention. In detail, the BAG6-specific chimeric antigen receptor expression plasmid according to the second embodiment, its insert fragment includes a promoter shown in SEQ ID NO:25, a fragment encoding a BAG6 antigen recognition domain shown in SEQ ID NO:13, a fragment encoding an HLA-G antigen recognition domain shown in SEQ ID NO:14, a fragment encoding a KIR transmembrane domain shown in SEQ ID NO:18, a fragment encoding a DAP12 signaling domain shown in SEQ ID NO:21, and a suicide gene (iCas9) shown in SEQ ID NO:24. The fragment encoding the HLA-G antigen recognition domain has a fragment encoding an HLA-G light chain immunoglobulin fragment and a fragment encoding an HLA-G heavy chain immunoglobulin fragment. The insert fragment is then constructed on a Creative Biolabs vector to obtain the BAG6-specific chimeric antigen receptor expression plasmid according to the second embodiment. The vector used is a lentiviral vector system, so the constructed BAG6-specific chimeric antigen receptor expression plasmid of Implementation Method 2 can be transfected into expression cells to produce lentivirus, and subsequently the BAG6-specific chimeric antigen receptor expression plasmid of Implementation Method 2 can be transduced into immune cells using the lentivirus.

[0096] Please refer to Fig.10, depicting the theoretical structure and action mechanism of the BAG6-specific chimeric antigen receptor of the second embodiment. The cell expressing the BAG6-specific chimeric antigen receptor of the second embodiment is a genetically engineered natural killer cell or T cell, which expresses the BAG6-specific chimeric antigen receptor of the second embodiment, and the BAG6-specific chimeric antigen receptor system is a tumor targeting receptor complex composed of a BAG6 antigen recognition domain, an HLA-G antigen recognition domain, a KIR transmembrane domain and a cytoplasmic domain, wherein the cytoplasmic domain is a DAP12 signaling domain, and preferably, it may further include a suicide protein, and the suicide protein may be iCas9. The BAG6-specific chimeric antigen receptor can specifically recognize BAG6 and / or HLA-G on the cell membrane of tumor cells, thereby toxicating the tumor cells. Preferably, when tumor cells are treated with chemotherapy drugs, BAG6 and HLA-G on the cell membrane of the tumor cells can be positively regulated, and the BAG6-specific chimeric antigen receptor binds to BAG6 and / or HLA-G specifically recognized on the surface of the tumor cells, triggering signal transduction, generating a signal cascade leading to the activation and proliferation of the cells expressing the BAG6-specific chimeric antigen receptor of the present invention, thereby inducing the exocytosis of lytic granules and killing the target tumor cells.

[0097] 3.1. Example 3

[0098] In this test example, the BAG6-specific chimeric antigen receptor of embodiment 2 of the present invention is transduced into primary T cells to obtain cells expressing the BAG6-specific chimeric antigen receptor of embodiment 3 of the present invention (hereinafter referred to as "Example 3"). The effect of Example 3 and a pharmaceutical composition for treating cancer comprising Example 3 on inducing death of breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells and ovarian cancer cells was further tested.

[0099] First, human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG, human pancreatic cancer cell line AsPC-1 and human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells / well, and then cultured for 48 hours before testing. In the test, each tumor cell was divided into 6 groups, namely, an untreated control group, a test group 1 treated with chemotherapeutic drugs, a test group 2 treated with parental primary T cells, a test group 3 treated with parental primary T cells and chemotherapeutic drugs, a test group 4 treated with Example 3, and a test group 5 treated with Example 3 and chemotherapeutic drugs. In the group of human breast cancer cell line MDA-MB-231, the chemotherapy drug used was doxorubicin (200nM); in the group of human malignant brain tumor cell line DBTRG, the chemotherapy drug used was temozolomide (80μg / mL); in the group of human pancreatic cancer cell line AsPC-1, the chemotherapy drug used was gemcitabine (20μM); in the group of human ovarian cancer cell line SKOV3, the chemotherapy drug used was carboplatin (20μM). In test group 4 and test group 5, the number of cells of Example 3 treated was 1×105, and the number of parental primary T cells treated in test group 2 and test group 3 was also 1×105. The treated cells in each group were then stained with Annexin V-FITC and PI, and the apoptosis and death of cells were detected by flow cytometry, and the total percentage of cells stained with Annexin V-FITC and / or PI was calculated to obtain the cytotoxic effect. Each group was tested independently in triplicate, and the cytotoxicity results were statistically analyzed.

[0100] Please refer to Fig.11A , Fig. 11B , Fig. 11C , Fig.11D , Fig.11E , Fig.11F , Fig.11G , Fig.11H Table 3 is a graph showing the analysis results of inducing tumor cell death in Example 3, wherein Fig. 11B , Fig.11D , Fig.11F and Fig.11H The "P" in the figure represents parental primary T cells. Fig.11A This is the analysis result of human breast cancer cell line MDA-MB-231. Fig. 11B for Fig.11A Statistical graph after three repeated experiments. Fig. 11C This is the analysis result of human malignant brain tumor cell line DBTRG. Fig.11D for Fig. 11C Statistical graph after three repeated experiments. Fig.11E This is the analysis result of human pancreatic cancer cell line AsPC-1. Fig.11F for Fig.11E Statistical graph after three repeated experiments. Fig.11G This is the analysis result of human ovarian cancer cell line SKOV3. Fig.11H for Fig.11G The statistical graph after three repeated experiments. Table 3 shows the mortality rate of each experimental group.

[0101] Table 3. Test results of Example 3

[0102]

[0103] From Table 3, Fig.11A and Fig. 11B The results showed that in the test groups of human breast cancer cell line MDA-MB-231, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 4 of treatment example 3 was about 27.3%, which was statistically significant compared with test group 2 (p<0.001). In addition, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 5 of treatment example 3 and doxorubicin was as high as 46.6%, which was statistically significant compared with test group 4 (p<0.01), and also statistically significant compared with test group 3 (p<0.001).

[0104] From Table 3, Fig. 11C and Fig.11D The results showed that among the test groups of human malignant brain tumor cell line DBTRG, the mortality rate of human malignant brain tumor cell line DBTRG induced by test group 4 of treatment example 3 was about 40.9%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human malignant brain tumor cell line DBTRG induced by test group 5 of treatment example 3 and temozolomide was more than 64%, which was statistically significant compared with test group 4 (p<0.05), and also statistically significant compared with test group 3 (p<0.001).

[0105] From Table 3, Fig.11E and Fig.11F The results showed that in the test groups of human pancreatic cancer cell line AsPC-1, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 4 of treatment example 3 was 48.2%, which was statistically significant compared with test group 2 (p<0.05). In addition, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 5 of treatment example 3 and gemcitabine was about 59.1%, which was statistically significant compared with test group 4 (p<0.05), and also statistically significant compared with test group 3 (p<0.01).

[0106] From Table 3, Fig.11G and Fig.11HThe results showed that in the test groups of human ovarian cancer cell line SKOV3, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 4 of treatment example 3 was about 37.7%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 5 of treatment example 3 and carboplatin was as high as 75.2%, which was statistically significant compared with test group 4 (p<0.001) and also statistically significant compared with test group 3 (p<0.001).

[0107] 3.2. Example 4

[0108] In this test example, the BAG6-specific chimeric antigen receptor of embodiment 2 of the present invention is transduced into primary natural killer cells to obtain cells expressing the BAG6-specific chimeric antigen receptor of embodiment 4 of the present invention (hereinafter referred to as "Example 4"). The effect of Example 4 and a pharmaceutical composition for treating cancer comprising Example 4 on inducing death of breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells and ovarian cancer cells was further tested.

[0109] First, human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG, human pancreatic cancer cell line AsPC-1 and human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells / well, and then cultured for 48 hours before testing. In the test, each tumor cell was divided into 6 groups, namely, an untreated control group, a test group 1 treated with chemotherapeutic drugs, a test group 2 treated with parental primary natural killer cells, a test group 3 treated with parental primary natural killer cells and chemotherapeutic drugs, a test group 4 treated with Example 4, and a test group 5 treated with Example 4 and chemotherapeutic drugs. In the group of human breast cancer cell line MDA-MB-231, the chemotherapy drug used was doxorubicin (200nM); in the group of human malignant brain tumor cell line DBTRG, the chemotherapy drug used was temozolomide (80μg / mL); in the group of human pancreatic cancer cell line AsPC-1, the chemotherapy drug used was gemcitabine (20μM); in the group of human ovarian cancer cell line SKOV3, the chemotherapy drug used was carboplatin (20μM). In test groups 4 and 5, the number of cells of Example 4 treated was 1×105, and the number of cells of parental primary natural killer cells treated in test groups 2 and 3 was also 1×105. The treated cells in each group were then stained with Annexin V-FITC and PI, and the total percentage of cells stained with Annexin V-FITC and / or PI was calculated to obtain the cytotoxic effect. After three independent replicates were performed for each group, the cytotoxic effect results were statistically analyzed.

[0110] Please refer to Fig. 12A , Fig. 12B , Fig. 12C , Fig.12D , Fig.12E , Fig.12F , Figure 12G , Fig.12H Table 4 is a graph showing the analysis results of inducing tumor cell death in Example 4, wherein Fig. 12B , Fig.12D , Fig.12F and Fig.12H The "P" in the expression represents parental primary natural killer cells. Fig. 12A This is the analysis result of human breast cancer cell line MDA-MB-231. Fig. 12B for Fig. 12A Statistical graph after three repeated experiments. Fig. 12C This is the analysis result of human malignant brain tumor cell line DBTRG. Fig.12D for Fig. 12C Statistical graph after three repeated experiments. Fig.12E This is the analysis result of human pancreatic cancer cell line AsPC-1. Fig.12F for Fig.12E Statistical graph after three repeated experiments. Figure 12G This is the analysis result of human ovarian cancer cell line SKOV3. Fig.12H for Figure 12G The statistical graph after three repeated experiments. Table 4 shows the mortality rate of each experimental group.

[0111] Table 4. Test results of Example 4

[0112]

[0113] The results of Tables 4, 12A and 12B show that, among the test groups of human breast cancer cell line MDA-MB-231, the death rate of human breast cancer cell line MDA-MB-231 induced by Test Group 4 of Treatment Example 4 was 33.9%, which was statistically significantly different from that of Test Group 2 (p<0.001). In addition, the death rate of human breast cancer cell line MDA-MB-231 induced by Test Group 5 of Treatment Example 4 and doxorubicin was as high as more than 80%, which was statistically significantly different from that of Test Group 4 (p<0.001), and also statistically significantly different from that of Test Group 3 (p<0.001).

[0114] From Table 4, Fig. 12C and Fig.12DThe results showed that among the test groups of human malignant brain tumor cell line DBTRG, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 4 of Treatment Example 4 was about 66.3%, which was statistically significant compared with Test Group 2 (p<0.01). In addition, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 5 of Treatment Example 4 and temozolomide was as high as 83.8%, which was statistically significant compared with Test Group 4 (p<0.05), and also statistically significant compared with Test Group 3 (p<0.001).

[0115] From Table 4, Fig.12E and Fig.12F The results showed that in the test groups of human pancreatic cancer cell line AsPC-1, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 4 of treatment example 4 was about 42.9%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 5 of treatment example 4 and gemcitabine was as high as 63.6%, which was statistically significant compared with test group 4 (p<0.001), and also statistically significant compared with test group 3 (p<0.001).

[0116] From Table 4, Figure 12G and Fig.12H The results showed that in the test groups of human ovarian cancer cell line SKOV3, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 4 of treatment example 4 was about 38.3%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 5 of treatment example 4 and carboplatin was as high as 77.7%, which was statistically significant compared with test group 4 (p<0.001) and test group 3 (p<0.001).

[0117] From Table 3, Table 4 and FIG. 11A to FIG. 12H The results show that the BAG6-specific chimeric antigen receptor cells of the second embodiment have excellent cytotoxic effects on breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells or ovarian cancer cells. Therefore, the BAG6-specific chimeric antigen receptor cells of the present invention can be used to prepare drugs for inducing tumor cell death in mammals. Figure 2A , Figure 2B and Figure 3The results show that treatment with chemotherapy drugs can increase the expression of BAG6 and HLA-G on the cell membrane of tumor cells, and the BAG6-specific chimeric antigen receptor expressed by the BAG6-specific chimeric antigen receptor expressing cells of embodiment 2 can specifically bind to BAG6 and HLA-G, so that treating the BAG6-specific chimeric antigen receptor expressing cells of embodiment 2 after treating chemotherapy drugs, or treating the BAG6-specific chimeric antigen receptor expressing cells of embodiment 2 and chemotherapy drugs at the same time, can have a better effect of killing tumor cells. It shows that the pharmaceutical composition for treating cancer of the present invention can preferably contain chemotherapy drugs, which can effectively kill tumor cells and thus treat cancer.

[0118] 4. Implementation Method 3

[0119] The BAG6-specific chimeric antigen receptor of the third embodiment comprises the BAG6 antigen recognition domain shown in SEQ ID NO:1, the B7-H6 antigen recognition domain shown in SEQ ID NO:3, the CD8 transmembrane domain shown in SEQ ID NO:5, the 4-1BB signaling domain shown in SEQ ID NO:11, and the CD3ζ signaling domain shown in SEQ ID NO:10, which are arranged in sequence from the N-terminus to the C-terminus. In addition, the BAG6-specific chimeric antigen receptor of the third embodiment may further comprise the suicide protein shown in SEQ ID NO:12, which is connected to the C-terminus of the CD3ζ signaling domain. The nucleic acid of the third embodiment comprises the fragment encoding the BAG6 antigen recognition domain shown in SEQ ID NO:13, the fragment encoding the B7-H6 antigen recognition domain shown in SEQ ID NO:15, the fragment encoding the CD8 transmembrane domain shown in SEQ ID NO:17, the fragment encoding the 4-1BB signaling domain shown in SEQ ID NO:23, and the fragment encoding the CD3ζ signaling domain shown in SEQ ID NO:22. In addition, the nucleic acid of embodiment 3 may further comprise a suicide gene as shown in SEQ ID NO: 24, which is connected to the 3' end of the fragment encoding the CD3ζ signal transduction domain.

[0120] Please refer to Fig.13, depicting a schematic diagram of the construction of a BAG6-specific chimeric antigen receptor expression plasmid according to Embodiment 3 of the present invention. In detail, the BAG6-specific chimeric antigen receptor expression plasmid according to Embodiment 3, its insert fragment comprises a promoter shown in SEQ ID NO:25, a fragment encoding a BAG6 antigen recognition domain shown in SEQ ID NO:13, a fragment encoding a B7-H6 antigen recognition domain shown in SEQ ID NO:15, a fragment encoding a CD8 transmembrane domain shown in SEQ ID NO:17, a fragment encoding a cytoplasmic domain, and a suicide gene (iCas9) shown in SEQ ID NO:24, arranged in sequence. The fragment encoding the B7-H6 antigen recognition domain comprises a fragment encoding a B7-H6 light chain immunoglobulin and a fragment encoding a B7-H6 heavy chain immunoglobulin, and the fragment encoding the cytoplasmic domain comprises a fragment encoding a 4-1BB signaling domain shown in SEQ ID NO:23, and a fragment encoding a CD3ζ signaling domain shown in SEQ ID NO:22. The insert fragment is then constructed on a Creative Biolabs vector to obtain a BAG6-specific chimeric antigen receptor expression plasmid of implementation mode 3. The vector used is a lentiviral vector system, so the constructed BAG6-specific chimeric antigen receptor expression plasmid of implementation mode 3 can be transfected into expression cells to produce lentivirus, and subsequently the BAG6-specific chimeric antigen receptor expression plasmid of implementation mode 3 can be transduced into immune cells using the lentivirus.

[0121] Please refer to Fig.14 , depicting the theoretical structure and mechanism of action of the BAG6-specific chimeric antigen receptor of the third embodiment. The cell expressing the BAG6-specific chimeric antigen receptor of the third embodiment is a genetically engineered natural killer cell or T cell, which expresses the BAG6-specific chimeric antigen receptor of the third embodiment, and the BAG6-specific chimeric antigen receptor system is a tumor-targeting receptor complex composed of a BAG6 antigen recognition domain, a B7-H6 antigen recognition domain, a CD8 transmembrane domain, and a cytoplasmic domain, wherein the cytoplasmic domain includes a 4-1BB signaling domain and a CD3ζ signaling domain, and preferably, may further include a suicide protein, and the suicide protein may be iCas9. The BAG6-specific chimeric antigen receptor can specifically recognize BAG6 and / or B7-H6 on the tumor cell membrane, thereby toxicating the tumor cells. Preferably, when tumor cells are treated with chemotherapeutic drugs, BAG6 and B7-H6 on the plasma membrane of tumor cells can be positively regulated, and the BAG6-specific chimeric antigen receptor binds to BAG6 and / or B7-H6 specifically recognized on the surface of tumor cells, triggering signal transduction, generating a signal cascade leading to the activation and proliferation of the cells expressing the BAG6-specific chimeric antigen receptor of the present invention, thereby inducing the exocytosis of lytic granules and killing the target tumor cells.

[0122] Example 5

[0123] In this test example, the BAG6-specific chimeric antigen receptor of embodiment 3 of the present invention is transduced into primary T cells to obtain cells expressing the BAG6-specific chimeric antigen receptor of embodiment 5 of the present invention (hereinafter referred to as "Example 5"). The effect of Example 5 and a pharmaceutical composition for treating cancer comprising Example 5 on inducing death of breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells and ovarian cancer cells was further tested.

[0124] First, human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG, human pancreatic cancer cell line AsPC-1 and human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells / well, and then cultured for 48 hours before testing. In the test, each tumor cell was divided into 6 groups, namely, an untreated control group, a test group 1 treated with chemotherapeutic drugs, a test group 2 treated with parental primary T cells, a test group 3 treated with parental primary T cells and chemotherapeutic drugs, a test group 4 treated with Example 5, and a test group 5 treated with Example 5 and chemotherapeutic drugs. In the group of human breast cancer cell line MDA-MB-231, the chemotherapy drug used was doxorubicin (200nM); in the group of human malignant brain tumor cell line DBTRG, the chemotherapy drug used was temozolomide (80μg / mL); in the group of human pancreatic cancer cell line AsPC-1, the chemotherapy drug used was gemcitabine (20μM); in the group of human ovarian cancer cell line SKOV3, the chemotherapy drug used was carboplatin (20μM). In test group 4 and test group 5, the number of cells of Example 5 treated was 1×105, and the number of parental primary T cells treated in test group 2 and test group 3 was also 1×105. The treated cells in each group were then stained with Annexin V-FITC and PI, and the apoptosis and death of cells were detected by flow cytometry, and the total percentage of cells stained with Annexin V-FITC and / or PI was calculated to obtain the cytotoxic effect. Each group was tested independently in triplicate, and the cytotoxicity results were statistically analyzed.

[0125] Please refer to Fig.15A , Fig. 15B , Fig. 15C , Fig.15D , Fig.15E , Fig.15F , Figure 15G , Fig.15H Table 5 is a graph showing the analysis results of inducing tumor cell death in Example 5, wherein Fig. 15B , Fig.15D , Fig.15F and Fig.15H The "P" in the figure represents parental primary T cells. Fig.15A This is the analysis result of human breast cancer cell line MDA-MB-231. Fig. 15B for Fig.15A Statistical graph after three repeated experiments. Fig. 15C This is the analysis result of human malignant brain tumor cell line DBTRG. Fig.15D for Fig. 15C Statistical graph after three repeated experiments. Fig.15E This is the analysis result of human pancreatic cancer cell line AsPC-1. Fig.15F for Fig.15E Statistical graph after three repeated experiments. Figure 15G This is the analysis result of human ovarian cancer cell line SKOV3. Fig.15H for Figure 15G The statistical graph after three repeated experiments. Table 5 shows the mortality rate of each experimental group.

[0126] Table 5. Test results of Example 5

[0127]

[0128] From Table 5, Fig.15A and Fig. 15B The results showed that in the test groups of human breast cancer cell line MDA-MB-231, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 4 of treatment example 5 was about 37.6%, which was statistically significant compared with test group 2 (p<0.001). In addition, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 5 of treatment example 5 and doxorubicin was as high as more than 50%, which was statistically significant compared with test group 4 (p<0.01), and also statistically significant compared with test group 3 (p<0.001).

[0129] From Table 5, Fig. 15C and Fig.15D The results showed that among the test groups of human malignant brain tumor cell line DBTRG, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 4 of Treatment Example 5 was about 40.9%, which was statistically significant compared with Test Group 2 (p<0.01). In addition, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 5 of Treatment Example 5 and temozolomide was more than 60%, which was statistically significant compared with Test Group 4 (p<0.01), and also statistically significant compared with Test Group 3 (p<0.001).

[0130] From Table 5, Fig.15E and Fig.15FThe results showed that in the test groups of human pancreatic cancer cell line AsPC-1, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 4 of treatment example 5 was about 41.3%, which was statistically significant compared with test group 2 (p<0.05). In addition, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 5 of treatment example 5 and gemcitabine was about 60%, which was statistically significant compared with test group 4 (p<0.05), and also statistically significant compared with test group 3 (p<0.01).

[0131] From Table 5, Figure 15G and Fig.15H The results showed that in the test groups of human ovarian cancer cell line SKOV3, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 4 of treatment example 5 was about 40.2%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 5 of treatment example 5 and carboplatin was as high as 75.1%, which was statistically significant compared with test group 4 (p<0.001) and also statistically significant compared with test group 3 (p<0.001).

[0132] 4.2. Example 6

[0133] In this test example, the BAG6-specific chimeric antigen receptor of embodiment 3 of the present invention is transduced into primary natural killer cells to obtain cells expressing the BAG6-specific chimeric antigen receptor of Example 6 of the present invention (hereinafter referred to as "Example 6"). The effect of Example 6 and a pharmaceutical composition for treating cancer comprising Example 6 on inducing death of breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells and ovarian cancer cells was further tested.

[0134] First, human breast cancer cell line MDA-MB-231, human malignant brain tumor cell line DBTRG, human pancreatic cancer cell line AsPC-1 and human ovarian cancer cell line SKOV3 were seeded in a 12-well plate at a density of 1×105 cells / well, and then cultured for 48 hours before testing. In the test, each tumor cell was divided into 6 groups, namely, an untreated control group, a test group 1 treated with chemotherapeutic drugs, a test group 2 treated with parental primary natural killer cells, a test group 3 treated with parental primary natural killer cells and chemotherapeutic drugs, a test group 4 treated with Example 6, and a test group 5 treated with Example 6 and chemotherapeutic drugs. In the group of human breast cancer cell line MDA-MB-231, the chemotherapy drug used was doxorubicin (200nM); in the group of human malignant brain tumor cell line DBTRG, the chemotherapy drug used was temozolomide (80μg / mL); in the group of human pancreatic cancer cell line AsPC-1, the chemotherapy drug used was gemcitabine (20μM); in the group of human ovarian cancer cell line SKOV3, the chemotherapy drug used was carboplatin (20μM). In test groups 4 and 5, the number of cells of Example 6 treated was 1×105, and the number of cells of parental primary natural killer cells treated in test groups 2 and 3 was also 1×105. The treated cells in each group were then stained with Annexin V-FITC and PI, and the total percentage of cells stained with Annexin V-FITC and / or PI was calculated to obtain the cytotoxic effect. After three independent replicates were performed for each group, the cytotoxic effect results were statistically analyzed.

[0135] Please refer to Fig.16A , Fig. 16B , Fig. 16C , Fig.16D , Fig.16E , Fig.16F , Figure 16G , Fig.16H Table 6 is a graph showing the analysis results of inducing tumor cell death in Example 6, wherein Fig. 16B , Fig.16D , Fig.16F and Fig.16H The "P" in the expression represents parental primary natural killer cells. Fig.16A This is the analysis result of human breast cancer cell line MDA-MB-231. Fig. 16B for Fig.16A Statistical graph after three repeated experiments. Fig. 16C This is the analysis result of human malignant brain tumor cell line DBTRG. Fig.16D for Fig. 16C Statistical graph after three repeated experiments. Fig.16E This is the analysis result of human pancreatic cancer cell line AsPC-1. Fig.16F for Fig.16EStatistical graph after three repeated experiments. Figure 16G This is the analysis result of human ovarian cancer cell line SKOV3. Fig.16H for Figure 16G The statistical graph after three repeated experiments. Table 6 shows the mortality rate of each experimental group.

[0136] Table 6. Test results of Example 6

[0137]

[0138] From Table 6, Fig.16A and Fig. 16B The results showed that in the test groups of human breast cancer cell line MDA-MB-231, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 4 of treatment example 6 was about 41.1%, which was statistically significant compared with test group 2 (p<0.01). In addition, the mortality rate of human breast cancer cell line MDA-MB-231 induced by test group 5 of treatment example 6 and doxorubicin was as high as 74.7%, which was statistically significant compared with test group 4 (p<0.001) and also statistically significant compared with test group 3 (p<0.001).

[0139] From Table 6, Fig. 16C and Fig.16D The results showed that among the test groups of human malignant brain tumor cell line DBTRG, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 4 of Treatment Example 6 was 66.3%, which was statistically significant compared with Test Group 2 (p<0.05). In addition, the mortality rate of human malignant brain tumor cell line DBTRG induced by Test Group 5 of Treatment Example 6 and temozolomide was close to 83.8%, which was statistically significant compared with Test Group 4 (p<0.001), and also statistically significant compared with Test Group 3 (p<0.001).

[0140] From Table 6, Fig.16E and Fig.16F The results showed that in the test groups of human pancreatic cancer cell line AsPC-1, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 4 of treatment example 6 was about 41.3%, which was statistically significant compared with test group 2 (p<0.001). In addition, the mortality rate of human pancreatic cancer cell line AsPC-1 induced by test group 5 of treatment example 6 and gemcitabine was about 63.7%, which was statistically significant compared with test group 4 (p<0.001), and also statistically significant compared with test group 3 (p<0.01).

[0141] From Table 6, Figure 16G and Fig.16HThe results showed that in the test groups of human ovarian cancer cell line SKOV3, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 4 of treatment example 6 was about 29.3%, which was statistically significant compared with test group 2 (p<0.05). In addition, the mortality rate of human ovarian cancer cell line SKOV3 induced by test group 5 of treatment example 6 and carboplatin was as high as 68.5%, which was statistically significant compared with test group 4 (p<0.001) and also statistically significant compared with test group 3 (p<0.01).

[0142] From Table 5, Table 6 and FIG. 15A to FIG. 16H The results show that the BAG6-specific chimeric antigen receptor cells of the third embodiment have excellent cytotoxic effects on breast cancer cells, glioblastoma multiforme cells, pancreatic cancer cells or ovarian cancer cells. Therefore, the BAG6-specific chimeric antigen receptor cells of the present invention can be used to prepare drugs for inducing tumor cell death in mammals. Figure 2A , Figure 2B and Figure 4 The results show that treatment with chemotherapy drugs can increase the expression of BAG6 and B7-H6 on the cell membrane of tumor cells, and the BAG6-specific chimeric antigen receptor expressed by the BAG6-specific chimeric antigen receptor expressing cells of embodiment 3 can specifically bind to BAG6 and B7-H6, so that treating the BAG6-specific chimeric antigen receptor expressing cells of embodiment 3 after treating chemotherapy drugs, or treating the BAG6-specific chimeric antigen receptor expressing cells of embodiment 3 and chemotherapy drugs at the same time can have a better effect of killing tumor cells. It shows that the pharmaceutical composition for treating cancer of the present invention preferably includes chemotherapy drugs, which can effectively kill tumor cells and thus treat cancer.

[0143] In summary, the BAG6-specific chimeric antigen receptor of the present invention has excellent specific binding ability to tumor cells, especially specific binding to BAG6 expressed on the cell membrane of tumor cells, so that the BAG6-specific chimeric antigen receptor expressing cells expressing the BAG6-specific chimeric antigen receptor of the present invention can specifically target tumor cells, avoid off-target effects, and effectively kill tumor cells, so that it can be used to prepare drugs that induce tumor cell death in mammals. The pharmaceutical composition for treating cancer of the present invention, comprising the BAG6-specific chimeric antigen receptor expressing cells of the present invention, can effectively kill tumor cells and thus treat cancer. The pharmaceutical composition for treating cancer further comprising a chemotherapeutic drug can further induce the cell membrane of tumor cells to express BAG6 in large quantities, thereby enhancing the toxic effect of the BAG6-specific chimeric antigen receptor expressing cells on tumor cells, so as to have a more excellent tumor cell toxic effect.

[0144] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with the profession can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. A BAG6-specific chimeric antigen receptor that specifically binds to BCL2-associated apoptosis gene 6 (BAG6), characterized in that: The BAG6-specific chimeric antigen receptor comprises: The BAG6 antigen recognition domain, transmembrane domain, and cytoplasmic domain are arranged in sequence from the N-terminus to the C-terminus; The BAG6 antigen recognition domain comprises a monoclonal antibody fragment specific to BAG6, and the amino acid sequence of the BAG6 antigen recognition domain is shown in SEQ ID NO:

1.

2. The BAG6-specific chimeric antigen receptor according to claim 1, characterized in that It further comprises an HLA-G antigen recognition domain as shown in SEQ ID NO: 2, which is connected to the C-terminus of the BAG6 antigen recognition domain, and the HLA-G antigen recognition domain comprises a monoclonal antibody fragment specific to human leukocyte antigen G (HLA-G).

3. The BAG6-specific chimeric antigen receptor according to claim 1, characterized in that It further comprises a B7-H6 antigen recognition domain as shown in SEQ ID NO: 3, which is connected to the C-terminus of the BAG6 antigen recognition domain. The B7-H6 antigen recognition domain comprises a monoclonal antibody fragment specific to B7-H6 (B7 homolog 6).

4. The BAG6-specific chimeric antigen receptor according to any one of claims 1 to 3, characterized in that The transmembrane domain is the CD28 transmembrane domain shown in SEQ ID NO:4, the CD8 transmembrane domain shown in SEQ ID NO:5, or the KIR transmembrane domain shown in SEQ ID NO:

6.

5. The BAG6-specific chimeric antigen receptor according to any one of claims 1 to 3, characterized in that The cytoplasmic domain is the IL2 receptor β chain signaling domain shown in SEQ ID NO:7, the modified CD3ζ signaling domain shown in SEQ ID NO:8, the DAP12 signaling domain shown in SEQ ID NO:9, the CD3ζ signaling domain shown in SEQ ID NO:10, the 4-1BB signaling domain shown in SEQ ID NO:11, or a combination thereof.

6. The BAG6-specific chimeric antigen receptor according to any one of claims 1 to 3, characterized in that It further comprises a suicide protein as shown in SEQ ID NO: 12, which is linked to the C-terminus of the cytoplasmic domain.

7. An isolated nucleic acid encoding the BAG6-specific chimeric antigen receptor according to claim 1, characterized in that: The nucleic acid comprises: SEQ ID NO: 13 shows a fragment encoding the BAG6 antigen recognition domain, a fragment encoding the transmembrane domain and a fragment encoding the cytoplasmic domain, arranged in sequence.

8. The isolated nucleic acid according to claim 7, characterized in that It further comprises a fragment encoding an HLA-G antigen recognition domain as shown in SEQ ID NO: 14, which is connected to the 3' end of the fragment encoding the BAG6 antigen recognition domain.

9. The isolated nucleic acid according to claim 7, wherein It further comprises a fragment encoding the B7-H6 antigen recognition domain as shown in SEQ ID NO: 15, which is connected to the 3' end of the fragment encoding the BAG6 antigen recognition domain.

10. The isolated nucleic acid according to any one of claims 7 to 9, characterized in that The encoding transmembrane domain fragment is the encoding CD28 transmembrane domain fragment shown in SEQ ID NO:16, the encoding CD8 transmembrane domain fragment shown in SEQ ID NO:17, or the encoding KIR transmembrane domain fragment shown in SEQ ID NO:

18.

11. The isolated nucleic acid according to any one of claims 7 to 9, characterized in that The encoding cytoplasmic domain fragment is the encoding IL2 receptor β chain signaling domain fragment shown in SEQ ID NO:19, the encoding modified CD3ζ signaling domain fragment shown in SEQ ID NO:20, the encoding DAP12 signaling domain fragment shown in SEQ ID NO:21, the encoding CD3ζ signaling domain fragment shown in SEQ ID NO:22, the encoding 4-1BB signaling domain fragment shown in SEQ ID NO:23, or a combination thereof.

12. The isolated nucleic acid according to any one of claims 7 to 9, characterized in that It further comprises a suicide gene as shown in SEQ ID NO: 24, which is connected to the 3' end of the fragment encoding the cytoplasmic domain.

13. A BAG6-specific chimeric antigen receptor expression plasmid, characterized in that: Include: The promoter shown in SEQ ID NO: 25 and the isolated nucleic acid according to any one of claims 7 to 9 are arranged in sequence.

14. The BAG6-specific chimeric antigen receptor expression plasmid according to claim 13, characterized in that: It further comprises a suicide gene as shown in SEQ ID NO: 24, which is connected to the 3' end of the nucleic acid.

15. A cell expressing a BAG6-specific chimeric antigen receptor, characterized in that: Include: immune cells; and The BAG6-specific chimeric antigen receptor expression plasmid as described in claim 13.

16. The cell expressing BAG6-specific chimeric antigen receptor according to claim 15, characterized in that: The immune cells are T cells or natural killer cells.

17. A pharmaceutical composition for treating cancer, characterized in that: Include: The BAG6-specific chimeric antigen receptor cell expressed as claimed in claim 15; and Pharmaceutically acceptable carrier.

18. The pharmaceutical composition for treating cancer according to claim 17, wherein It also includes chemotherapy drugs.

19. The pharmaceutical composition for treating cancer according to claim 18, wherein The chemotherapy drugs are doxorubicin, temozolomide, gemcitabine, or carboplatin.

20. A use of a cell expressing a BAG6-specific chimeric antigen receptor as claimed in claim 15, characterized in that: The invention is used for preparing a drug for inducing death of a tumor cell of a mammal, and the tumor cell is a breast cancer cell, a glioblastoma multiforme cell, a pancreatic cancer cell or an ovarian cancer cell.